HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $65 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $65 price target.